"In a very difficult to treat patient population, Prescient is delighted to report that two patients had a complete response (CR) to treatment, meaning total eradication of disease. This is an improvement on the already encouraging single agent activity of PTX-200 in the Phase 1 monotherapy study. Some peculiar toxicities were observed in three AML patients, including stomatitis, appendicitis and a small bowel obstruction, which were not seen in the Phase 1 study of PTX-200 as a monotherapy, nor in the other PTX-200 trials. Transaminase elevation was observed in three subjects, although only one was dose limiting".
Most relapsed cancer have significantly worse prognosis than intitial cancer. Survival rates decrease significantly. I'm not completely sure what the existing remission rates are for relapsed AML & how they are comparable taking into consideration the treatment pathway used in PTX trial but 2 complete remissions from 13 treatments seems promising without knowing the current state of the other 11 patients. The side effects (toxicities) are important to note.
PTX Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
